CICC Capital led a $100m Series C round in METiS Pharmaceuticals.

Synopsis

CICC Capital, a Chinese partially state-owned multinational investment management and financial services company, led a $100m Series C round in METiS Pharmaceuticals, a biotechnology company that aims to address unmet clinical needs. The firm will use the proceeds to advance its AI-driven drug delivery and discovery platform.

Principals

target

Metis Pharmaceuticals

bidder

China International Capital Corporation (cicc)

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Dealmakers (2)

Service Providers

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.